KBC - I am very surprised to see you using information that is from 20 June 2016. In the Jan. 2017 presentation they mention "Possible US market IPO when conditions permit" and in the Feb. 2017 presentation there is no mention of an IPO at all. In retrospect this is all quite curious.

After looking through the Feb. 2017 presentation I noticed on slide 25 that there are up to 20 drugs that ZEN3694 will work in combination with. One of those drugs, Trametinib, an MEK is used with Melanoma, Breast cancer and Lung cancer. Upon future research it looks as if those 3 cancers are in the top 4 most diagnosed cancers in the USA and possibly the world. Trametinib is a product of GSK.

I wonder if there are any discussions going on between GSK and Zenith at this time?

tada